TABLE 4:
Summary of antimicrobial susceptibility data from evaluable cases upon entry (day 0 (D0)) and withdrawal (WD), by treatment (clinical study)
| Otic Solution—treated cases, successful outcomes (D0) | Otic Solution—treated cases, failed outcomes (D0) | Otic Solution—treated cases, failed outcomes (WD) | ||||
| MIC range (µg/ml) | (MIC50)* | MIC range (µg/ml) | (MIC50)* | MIC range (µg/ml) | (MIC50)* | |
| Escherichia coli | 8–32 (n=6) | 8 | 4–16 (n=4) | 16 | 8–16 (n=3) | 16 |
| Proteus mirabilis | 4–8 (n=2) | NA | 4 (n=1) | NA | 8 (n=1) | NA |
| Pseudomonas aeruginosa | >64 (n=5) | NA | 64 to >64 (n=7) | >64 | >64 (n=5) | NA |
| Staphylococcus pseudintermedius | 2–8 (n=58) | 4 | 2–4 (n=16) | 4 | 4 (n=9) | NA |
| Beta-haemolytic Streptococci species | 2 (n=6) | NA | 2 (n=4) | NA | 2 (n=4) | NA |
| Malassezia pachydermatis | 0.008–0.25 (n=85) | 0.03 | 0.015–0.06 (n=23) | 0.03 | 0.008–0.06 (n=5) | 0.03 |